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Paula M Kelly7, Christina Lampe8, Johanna H van der Lee9, Thierry Odent10, Ralph Sakkers11, Maurizio Scarpa12,
Matthias U Schafroth13, Peter A Struijs13, Vassili Valayannopoulos14, Klane K White15 and Frits A Wijburg1*Abstract
Background: Mucopolysaccharidosis type I (MPS-I) is a lysosomal storage disorder characterized by progressive
multi-organ disease. The standard of care for patients with the severe phenotype (Hurler syndrome, MPS I-H) is
early hematopoietic stem cell transplantation (HSCT). However, skeletal disease, including hip dysplasia, is almost
invariably present in MPS I-H, and appears to be particularly unresponsive to HSCT. Hip dysplasia may lead to pain
and loss of ambulation, at least in a subset of patients, if left untreated. However, there is a lack of evidence to
guide the development of clinical guidelines for the follow-up and treatment of hip dysplasia in patients with MPS
I-H. Therefore, an international Delphi consensus procedure was initiated to construct consensus-based clinical
practice guidelines in the absence of available evidence.
Methods: A literature review was conducted, and publications were graded according to their level of evidence.
For the development of consensus guidelines, eight metabolic pediatricians and nine orthopedic surgeons with
experience in the care of MPS I patients were invited to participate. Eleven case histories were assessed in two
written rounds. For each case, the experts were asked if they would perform surgery, and they were asked to
provide information on the aspects deemed essential or complicating in the decision-making process. In a
subsequent face-to-face meeting, the results were presented and discussed. Draft consensus statements were
discussed and adjusted until consensus was reached.
Results: Consensus was reached on seven statements. The panel concluded that early corrective surgery for MPS
I-H patients with hip dysplasia should be considered. However, there was no full consensus as to whether such a
procedure should be offered to all patients with hip dysplasia to prevent complications or whether a more
conservative approach with surgical intervention only in those patients who develop clinically relevant symptoms
due to the hip dysplasia is warranted.
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Conclusions: This international consensus procedure led to the construction of clinical practice guidelines for hip
dysplasia in transplanted MPS I-H patients. Early corrective surgery should be considered, but further research is
needed to establish its efficacy and role in the treatment of hip dysplasia as seen in MPS I.
Keywords: Mucopolysaccharidosis type I, Hurler syndrome, Hematopoietic stem cell transplantation, Dysostosis
multiplex, Hip dysplasia, Surgical treatment, ConsensusBackground
Mucopolysaccharidosis type I (MPS I) is an autosomal re-
cessive lysosomal storage disorder caused by a deficiency
of the lysosomal hydrolase α-L-iduronidase (IDUA) [1].
The progressive accumulation of the glycosaminoglycans
(GAGs) heparan sulfate and dermatan sulfate in virtually
all body tissues leads to progressive multisystem disease.
MPS I encompasses a wide phenotypic spectrum, with the
attenuated end of this spectrum (Scheie syndrome; MPS I-
S) characterized by progressive musculoskeletal, pulmonary
and cardiac disease and a relatively normal life expectancy.
On the other end of the spectrum is severe Hurler syn-
drome (MPS I-H), which is the most prevalent phenotype,
with progressive central nervous system (CNS) disease in
addition to generally more severe somatic manifestations,
resulting in a significantly reduced life expectancy if left
untreated [2].Figure 1 Sequential X-ray studies of a MPS I-H patient who underwen
fusion at the age of 7. Characteristic signs included acetabular dysplasia w
characteristic medial thinning of the femoral head and coxa valga. A: at diaThe skeletal disease associated with MPS I is generally
referred to as ‘dysostosis multiplex’, a collection of radio-
graphic abnormalities resulting from defective endochon-
dral and membranous growth throughout the body [3-5].
Typically, the growth of the long bones is stunted, verte-
bral bodies are hypoplastic, which may result in kyphosis
with or without scoliosis, and the knees are in the valgus
position. Hip abnormalities, due to failure of ossification
of the lateral acetabular roof, medial proximal epiphyseal
growth failure of the femur and coxa valga, lead to a com-
plex form of hip dysplasia that is often accompanied by
deformation, subluxation or dislocation of the femoral
head (Figure 1). Other findings include bullet-shaped me-
tacarpals and phalanges, an enlarged and thickened skull,
broad clavicles and broad oar-shaped ribs [6,7]. The
pathophysiology of the skeletal disease in MPS I, as in
the other mucopolysaccharidoses, is complex and not fullyt successful HSCT at the age of 2 yrs and 6 m as well as spinal
ith a steep acetabular angle, interruption of Shenton’s line,
gnosis, age 1 yrs 3 m B: at 2 yrs 4 m C: at 4 yrs 8 m D: at 8 yrs 5 m.
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leads to impaired cell-to-cell signaling, altered mechanical
properties and upregulated inflammatory pathways, which
are all believed to affect the growth plate, osteoclasts and
osteoblasts while contributing to the typical bone path-
ology [8,9]. Furthermore, accumulation of GAGs in the
soft tissues and the consequent pathological cascade may
contribute to joint stiffness and limited mobility.
While intravenous enzyme replacement therapy (ERT;
recombinant IDUA, laronidase) is indicated for the treat-
ment of the non-neurological manifestations of MPS I
[10], hematopoietic stem cell transplantation (HSCT) is
the treatment of choice for patients with the MPS I-H
phenotype. In contrast to ERT, HSCT can preserve cogni-
tive function in addition to ameliorating many of the som-
atic symptoms of MPS I [11,12]. Due to the progressive
nature of the CNS disease, HSCT should be performed at
an early stage of the disease, preferably before the age of
2.5 years [10].
Although HSCT has shown favorable effects related to
several important clinical outcome parameters, the skel-
etal disease is particularly unresponsive to this treatment,
with a variable progression of genu valgum, thoracolum-
bar kyphosis and hip dysplasia [3,13-19].
Several studies have shown that hip dysplasia is very
common in patients with MPS I-H, even following success-
ful HSCT, and that it generally has a progressive course, as
observed on sequential radiographic studies [3,13-19]. Ad-
vanced hip disease in successfully transplanted MPS I-H
patients may lead to pain and functional complaints in
adolescence or early adulthood, at least in a subset of pa-
tients, as reported in a number of case series [3,14].
There are two approaches to treat hip dysplasia asso-
ciated with MPS I: 1) early corrective surgery and 2)
surgery to treat clinical symptoms such as pain and
functional disability. First, early corrective osteotomies
(e.g., Salter, Dega or Pemberton innominate osteotomies,
with or without femoral varus osteotomies [20-22]),
which aim to correct the anatomical abnormalities seen
in these patients, can be performed when the femoral
head and acetabulum are still sufficiently congruent. Be-
cause of the lack of sufficient remodeling potential of
the femur and acetabulum, these procedures are best
performed before the age of 6–7 years or earlier to at-
tempt to prevent progressive deformity. Second, salvage
procedures (e.g., a shelf augmentation or Chiari osteot-
omy [23]), can be performed at a later age when correct-
ive osteotomies are not feasible, as these procedures do
not require congruent hips. The main indication for
these salvage procedures is to reduce pain from sub-
luxation, and to increase bone stock for future hip
replacement.
As HSCT is increasingly successful due to improved
conditioning regimens and different stem cell sources,over 80% of patients now remain alive and engrafted
with a significantly improved life expectancy [24,25].
However, there is a paucity of data regarding which suc-
cessfully transplanted patients will develop hip dysplasia,
which patients will develop symptoms of hip dysplasia,
such as pain and impaired locomotion, and when surgi-
cal intervention is needed in patients with hip dysplasia.
There is thus a need for consensus-based guidelines. To
develop such guidelines in the absence of evidence, we
initiated an international expert consensus procedure
and used a modified Delphi technique, with the aim to
provide consensus-based treatment recommendations
on hip dysplasia in MPS I patients.
Methods
A modified Delphi technique was used to explore expert
opinions and obtain a consensus where possible, as this
method recognizes the value of experts’ opinions, ex-
perience and intuition when full scientific knowledge is
lacking [26].
As a first step in the procedure, a literature review was
performed by one of the researchers (EJL) to identify all
published material on the treatment strategies used in
MPS I patients with hip disease. A search was conducted
in the electronic databases of PubMed (www.pubmed.gov)
and EMBASE (www.embase.com) using the key words
‘mucopolysaccharidosis type I; MPS I; hip; dysplasia; treat-
ment’. Papers were included when they described MPS I
patients and contained descriptions of treatment (ERT or
HSCT), prevalence of hip dysplasia in the reported cohort,
treatment strategies for the hip dysplasia and outcomes of
the intervention. Papers were excluded if only the preva-
lence of hip dysplasia was reported without data on the
clinical course, intervention or outcome. Only original
papers reporting on patients cohorts were included. The
selected papers were summarized with a focus on the
outcomes of surgery; this overview was presented and
discussed during the face-to-face meeting. Eight metabolic
pediatricians (MB, EC, PRH, PMvH, SAJ, MS, VV, FAW)
and nine orthopedic surgeons (AB, AF, PMK, CL, TO,
RJS, MUS, PAS, KKW) were invited to participate in the
Delphi panel. All invitees had significant experience in the
treatment of patients with MPS I. When possible, an
orthopedic surgeon and a pediatrician were invited from
the same center. In addition, one orthopedic surgeon spe-
cializing in the treatment of adult patients with lysosomal
storage disorders and hip replacement surgery was invited
(MUS).
The procedure consisted of two written rounds and a
face-to-face meeting. For the written rounds, 11 case
histories were gathered from two participating centers
(Manchester, UK; Amsterdam, the Netherlands), cover-
ing both the severe and milder forms of hip abnormal-
ities as well as all MPS I phenotypes. For each patient,
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and treatment (ERT or HSCT, time of initiation) was pro-
vided. For each case, the clinical course was reported, with
a focus on psychomotor development, mobility and pain.
Sequential radiographic images (X-ray, CT or MRI) were
provided. If surgery had been performed, only the clinical
course and radiographic images prior to the surgical inter-
vention were reported, and the decision whether to oper-
ate was not reported. The case series included nine MPS
I-H patients, one MPS I-S patient and one patient with
the intermediate Hurler-Scheie phenotype.
In all written rounds, the panel members received the
cases in random order together with a survey asking for
each case whether they would choose to perform surgery
(yes / no / might consider but need more information).
In addition, in the first written round, the experts were
asked for each case description to state essential aspects
leading to the decision and issues complicating the deci-
sion making. These open-ended responses were subse-
quently categorized by two independent investigators
(JvL, EL).
Draft statements on the optimal approach to hip dys-
plasia in MPS I patients, based on the literature review
and clinical experience, were composed by three of the
authors (FAW, EJL, SAJ).
Approximately one month after the first written round,
a face-to-face meeting was held in Amsterdam, the
Netherlands. This meeting was chaired by an independent
moderator (JvL) not involved in the treatment of patients
with MPS I. Before beginning the actual meeting, the sec-
ond written round was performed. All 11 cases were again
presented to the participants (in a randomly different
order), and they were asked whether they would choose to
perform surgery (yes / no / might consider but need more
information). Statistical analyses for intra-observer vari-
ation and reliability of agreement were performed using
SPSS 19.0. Intra-observer reliability was quantified for
every specialist using Cohen’s kappa [27], whereas the
inter-rater reliability was assessed using Fleiss’ kappa; both
of these are measures of agreement that correct for agree-
ment by chance. Kappa values may vary from ≤ 0 (complete
disagreement, besides expected agreement based on prob-
ability) to 1 (complete agreement). Generally, a kappa value
of 0.61-0.80 is considered to indicate “good agreement”
[28]. This second written round was followed by detailed
discussions concerning the most appropriate treatment ap-
proach for each patient, with a particular focus on areas of
controversy. These discussions were fuelled by the infor-
mation on issues complicating decision making, as given
during the first written round. The aim of this discussion
was to gather all relevant issues related to the decision-
making processes concerning treatment decisions.
In the second phase of the face-to-face meeting, the
draft consensus statements were discussed and reviseduntil a full consensus was reached on each of the state-
ments. This resulted in the proposed recommendations
for follow-up and treatment of patients with hip path-
ology due to MPS I-H.
Results
The literature search resulted in 14 papers related to hip
dysplasia in MPS I. Six of these papers evaluated the man-
agement of hip dysplasia in MPS I and were further ana-
lyzed. The maximum recorded follow-up duration was
19 years post-HSCT. In two manuscripts, there was over-
lap in the reported patients, and one paper did not indi-
cate the number of surgeries performed. The remaining
four papers reported on 56 patients; the outcomes of
surgery for hip dysplasia in 28 patients were reported
(Table 1).
All 17 invited specialists accepted the invitation and
took part in the first written round. One pediatrician and
one orthopedic surgeon from two different centers were
unable to attend the face-to-face meeting due to severe
weather conditions and disruption of air travel, so 15 spe-
cialists participated in the face-to-face meeting and the
second written round. Tables 2 and 3 show the four most
commonly reported items considered to be important for,
or complicating, the decision-making process.
Fleiss’ kappa as a measure for inter-rater reliability was
0.19 and 0.13 in the first and second rounds respectively,
indicating that consensus amongst the specialists had not
changed before the face-to-face meeting The median
[range] Cohen’s kappa, indicating intra-rater reliability be-
tween the first and second round, was 0.43 [−0.16 to 0.72].
The following case illustrates the consensus procedure.
Case: Female MPS I patient, diagnosed at the age of
8 months. Presenting symptoms included respiratory tract
infections and course facial features. She was treated with
ERT (Aldurazyme®) for two months prior to successful
haematopoietic stem cell transplantation at age 13 months.
Currently, at the age of 4 years, she shows a delay in
motor and cognitive development. She has a normal range
of motion, reasonable locomotion with a wide gait. She is
able to run and climb, with some mild complaints of tired-
ness in both legs (Figure 2).
Participants responded to the question “Considering
the provided clinical and radiological data, would you
choose to perform surgery in this patient?” as follows:
No 47%, Yes 29%, Maybe 24%.
Highlights from the discussion:
 For 80% of specialists who favoured surgical
intervention, the appearance and progression of
radiological features was an argument for their decision.
 For 62% of the specialists who were against surgical
intervention, the absence of complaints was an
argument for their decision.
Table 1 Summary of literature on the treatment of hip dysplasia in transplanted MPS I-H patients
First author
(year of
publication)
Patients with hip
dysplasia (total
patients reported)
Surgical interventions
(n/o patients)
Mean age at
surgery
(years)
Mean follow-up
after surgery
(years)
Radiological
outcome
Functional outcome
Field (1994) 11 (11) Femoral osteotomy (?) - - No acetabular
remodeling
-
Souillet (2003) 11 (15) Acetabular and femoral
osteotomy (1)
7.4 1.4 No dislocation -
Femoral osteotomy (7)
Total hip replacement (1)
Weisstein (2004) 6 (7) Acetabular and femoral
osteotomy (4)
4.8 - Mean acetabular
angle from 38°
to 20°
Normal range of motion
in 4/6
Pelvic osteotomy (2) Appropriate
femoral head
coverage
Taylor (2008) 23 (23) Acetabular and femoral
osteotomy (8)
4.4 8.0 Mean acetabular
angle from 34°
to 22°
Good range of motion
Acetabular osteotomy (4) Mean center
edge-angle 40°
(long term)
Number of older patients
complaining of hip
discomfortFemoral osteotomy (1)
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discussion was whether future complaints were
expected or not. Specialists in favour of surgical
intervention all expected complaints, specialists who
favoured a conservative approach argued that
severity of radiological features did not match
(future) clinical complaints.
 Early intervention was thought to improve changes
of orthopaedic success and to improve anatomical
outcomes for later interventions
 No consensus was reached on this case
During discussion of the case histories and the draft
statements, it became clear to all participants that
obtaining a consensus and formulating clinical guide-
lines for the treatment of hip dysplasia for all MPS I
phenotypes was not feasible due to the broad phenotypic
spectrum of MPS I, the rarity of patients with more at-
tenuated phenotypes and the complete lack of published
case reports on more attenuated patients. As the severe
MPS I-H phenotype is the most prevalent of the MPS I
phenotypes and hip dysplasia appears to be uniformlyTable 2 The four most frequently reported aspects that were
process
Dec
Yes No
Essential aspects Radiological features (progression) Absen
Presence of pain Absen
Presence of disability Radiol
Expected progression of symptoms Stablepresent in MPS I-H, it was decided to limit the recom-
mendations to transplanted MPS I-H patients; from then
on, only case histories of MPS I-H patients (nine of the
11 case histories) were further discussed.
Full consensus was reached on the following seven
statements.
1. Hip dysplasia is a very common symptom in MPS I-
H patients. The anatomical abnormalities are
generally progressive, even after successful HSCT,
and may result in significant morbidity and
functional impairment.co
isi
ce
ce
og
clHSCT cannot prevent or stabilize progression of the
hip abnormalities in most patients [3,17,18,29].
Although data on the long-term follow-up of
transplanted MPS I-H patients are very limited, the
radiological characteristics, such as (sub)luxation of
the hips and decreased articular cartilage, suggest
that hip dysplasia may ultimately result, at least in a
subgroup of patients, in pain and loss of function.
2. The rate of progression of hip dysplasia in
successfully transplanted MPS I-H patients varies,nsidered essential for the surgical decision-making
on to perform surgery
Might consider
of pain Radiological features
of disability Absence/presence of pain
ical features (stable course) Absence/presence of disability
inical course so far Expected progression of symptoms
Table 3 The four most frequently reported aspects complicating surgical decision making
Decision to perform surgery
Yes No Might consider
Complicating aspects Radiological features (complicating surgery) Radiological features without pain Radiological features
Absence of pain Lack of evidence Absence/presence of pain
Progression of symptoms so far Absence of disability Unclear prognosis with/without surgery
Expected progression of symptoms Stable clinical course so far Absence/presence of disability
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progression or the risk for development of
symptoms attributable to MPS I-H-related hip
dysplasia.
Because the pathophysiology of hip dysplasia in
MPS I-H patients differs from the relatively
common developmental dysplasia of the hip (DDH),
data on the course of the disease in DDH cannot be
used to predict the course of the hip dysplasia in
transplanted MPS I-H patients. In addition, the
severity of hip abnormalities as assessed by
radiographic studies varies significantly within the
transplanted Hurler population [3,13-19].The risk
for pain and functional disability is likely to be
correlated with the severity of abnormalities (i.e.,
(sub)luxation of the femoral head, steep acetabular
angle) at an early age. However, other factors such
as age at transplantation, donor chimerism, extent of
somatic and neurological residual disease and overall
mobility may also influence the clinical course and
therefore the risk for the development of pain.
3. The presence and severity of hip abnormalities
should be assessed soon after the diagnosis of MPS I
in all patients. This should be done according to
radiographic studies and include at least an AP
pelvic X-ray study.Figure 2 Pelvic X-ray at age 4 years.Although predicting the clinical course of hip
abnormalities is currently very difficult, or even
impossible, in individual patients with MPS I-H,
early assessment of hip abnormalities is important
for the early identification of patients with hip
dysplasia. Future treatment decisions can then be
based upon serial radiographic studies, allowing
assessment of the rate of progression.
4. Patients with MPS I-H should be followed up
regularly from the time of diagnosis by a multi-
disciplinary team. This team should include a
pediatric orthopedic surgeon.
A multi-disciplinary team composed of specialists
from various medical disciplines and including other
healthcare professionals such as physiotherapists is
needed for optimal care during the follow-up of
MPS I-H patients [30]. To allow for early
discussions on the optimal treatment strategy in
individual patients and timely surgery, a pediatric
orthopedic surgeon should be a member of the
multidisciplinary MPS I team rather than only
available upon consultation.
5. Hip surgery should be considered as a treatment
option in all transplanted MPS I-H patients with hip
dysplasia.
Early reconstructive surgery is primarily aimed at
the prevention of complications (pain, dislocation)
later in life and needs to be performed at a relatively
early age, before deformation of the femoral head.
This approach was considered optimal by a majority,
but not all of the panelists. As not all patients will
develop pain and/or hip dislocation, specialists may
also choose to monitor the hip dysplasia and only
consider surgery when symptoms develop that
interfere with the patient’s quality of life. As this
generally occurs later in life, reconstructive surgery
will often not be feasible, and a salvage procedure,
aimed at stabilizing the femoral head to prevent full
dislocation, will then be the treatment of choice.
This latter approach was considered optimal by a
minority of the panelists.
As life expectancy of transplanted MPS I patients
has increased considerably and total hip replacement
is probably an important future treatment option for
osteoarthritis of the hips in adult patients both early
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Pemberton procedure) and late salvage surgery
should aim for creating sufficient bone stock for
later hip replacement surgery.
Patients with chronic pain due to advanced hip
disease and for whom a salvage procedure or a total
hip replacement is not feasible due to anatomical
deformation or other complicating factors should be
treated with chronic pain medication or by a resection
arthroplasty of the hips (Girdlestone procedure).
6. If a patient expresses pain that is likely located in the
hips, it is important to try to establish whether the
pain is caused by arthropathy.
Chronic hip pain due to arthropathy that impacts
the patient’s quality of life or necessitates chronic
pain medication can be an indication for hip surgery.
However, it can be difficult to assess whether the
pain is indeed caused by arthropathy, especially in
children. Even after successful transplantation, MPS
I-H patients may have significant residual disease,
such as lumbar kyphosis, myelopathy, joint stiffness
and genu valgum, which may impair locomotion and
result in hip pain. An intra-articular injection of
local anesthetics may be considered as a tool to
establish whether the pain is caused by intra-
articular pathology.
7. For all patients for whom surgical intervention is
considered, a number of factors need to be taken
into account. These include life expectancy,
neurological status, musculoskeletal symptoms,
expected rehabilitation course, general condition,
anesthetic risks, expected mobility with or without
surgery and quality of life.
Decisions regarding hip surgery in transplanted MPS
I-H patients need to be carefully balanced, and a
number of factors need to be taken into account.
Despite the considerably improved outcome of
HSCT, life expectancy in successfully transplanted
MPS I-H patients may still be reduced due to
residual MPS I-H-related disease. This should be
taken into account when surgery aimed at the
prevention of long-term complications like arthritis
is considered. A more conservative approach, e.g.,
long-term use of analgesics, may also be considered.
In addition, once full dislocation has occurred, this
may reduce or even fully abolish the pain.
Furthermore, neurological and musculoskeletal
disease may significantly complicate the final
functional outcome of hip surgery. Some patients
may lose their ability for independent locomotion
and may become fully wheelchair-bound before
adulthood due to causes other than hip disease.
Other MPS I-H-related symptoms, such as cognitive
impairment, may also impact the potential forrehabilitation after surgery. Finally, a number of
other MPS I-H-related issues, such as spinal
deformity, upper airway disease, cardiomyopathy or
restrictive lung disease [31], may result in increased
anesthetic and perioperative risks.Discussion
This international consensus procedure was initiated to
develop clinical practice guidelines for the management
of hip dysplasia in patients with MPS I. Because of the
broad phenotypic spectrum of MPS I, the high preva-
lence of hip dysplasia in MPS I-H patients and the lack
of published cases or case series on patients with a more
attenuated phenotype, it was decided to focus on MPS I-
H patients during the consensus meeting. The consider-
able increase in life expectancy of MPS I-H patients due
to the improved outcome of HSCT has revealed that
many patients suffer from progressive, residual ortho-
pedic disease [3,14-19,32], which underpins the need
for the development of practice guidelines. Ideally, best
practice guidelines are based upon systematic reviews
(level 1 evidence; Oxford Centre for Evidence Based
Medicine; www.cebm.net) or prospective, randomized
controlled trials (level 2 evidence). Randomized con-
trolled trials are, however, extremely difficult to perform
in a very rare and heterogeneous disease such as MPS I-
H. Additionally, such studies are further complicated
by the very long follow-up period of at least 20 years
needed to assess the effects of any intervention, com-
pared to a more conservative wait-and-see-approach for
hip dysplasia. At present, there are only case series on
the surgical management of hip dysplasia reported in
the literature (level 4 evidence, Table 1), and these stud-
ies do not report on the effects of surgery on long-term
complications such as osteoarthritis [3,15-18].
In the absence of sufficient data to make an evidence-
based clinical practice protocol, we decided to use the
Delphi technique, as this allows the combination of
available evidence with expert opinion to develop guide-
lines. Structured feedback on the responses gathered
then allows for a focused discussion and leaves room for
a variety of opinions.
Full consensus was reached on a number of important
issues. However, there was no full consensus as to the
essential question of whether early corrective hip surgery
is the optimal treatment for all transplanted MPS I-H
patients with hip dysplasia on radiographic studies. Most
experts preferred early corrective surgery to prevent pro-
gressive hip subluxation and subsequent arthrosis. Since
not all patients develop hip pain or functional disabilities
as a consequence of hip dysplasia, at least not before
early adolescence, a minority of panel members opted
for a more conservative approach. They elected surgical
intervention only if chronic hip pain, due to the
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velops. In the absence of data on both the natural course
of hip dysplasia in MPS I-H without surgical intervention
and on the long-term outcome of early corrective surgery
in transplanted MPS I-H patients, it is recommended that
decisions on treatment should be based on evaluation by a
multi-disciplinary team, weighing the pros and cons of
early corrective surgery.
The current study had several limitations. First, the Del-
phi technique was developed to explore expert opinions
and converge these towards a “mean”, which might suggest
a scientific truth, which is not evidence based. Additionally,
despite convergence, the influence of “strong personalities”
cannot be fully overcome. Potential “molding of opinions”
by the investigators was addressed by the choice of an in-
dependent moderator [33].
Second, there were two deviations from the initial
study design. The inability of two participants to attend
the face-to-face meeting led to a lower number of re-
sponders. Additionally, the decision to focus on MPS I-
H patients rather than on discussing treatment options
for the full phenotypic spectrum left some patient cases
redundant.
This consensus procedure resulted in a framework of
clinical practice guidelines that can be used in the follow-
up and management of hip dysplasia in patients with MPS
I-H. Despite this narrowed focus, we feel that many of the
statements might also be applicable for Hurler/Scheie or
Scheie patients with severe hip dysplasia. Furthermore, it
must be stressed that clinical practice guidelines can never
replace the physician’s clinical judgment. Future research
on the natural history of hip dysplasia in all MPS I pheno-
types and on the long-term outcomes of early surgical
intervention is much needed but difficult to perform. Fo-
cusing on patient quality of life and functional outcomes
is essential, considering the variability of residual disease
seen in transplanted MPS I-H patients, and the general
lack of correlation between radiology findings and patient
reported outcomes.Conclusions
This international consensus procedure led to the con-
struction of clinical practice guidelines for hip dysplasia in
transplanted MPS I-H patients. Early corrective surgery
should be considered, but further research is needed to es-
tablish its efficacy and role in the treatment of hip dyspla-
sia as seen in MPS I.
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